Fatty liver natural history, complications and prognosis: Difference between revisions
(Created page with "__NOTOC__ {{Fatty liver}} {{CMG}} Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing. == Complicat...") |
No edit summary |
||
| (10 intermediate revisions by 3 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Natural History== | |||
[[Image:Stage of liver damage.JPG|left|Different stages of liver damage]] | |||
<br clear="left" /> | |||
== Complications == | == Complications == | ||
Up to 10% of cirrhotic alcoholic FLD will develop [[hepatocellular carcinoma]]. Overall incidence of liver cancer in non-alcoholic FLD has not been assessed yet but the association is well established<ref>{{cite journal |author=Qian Y, Fan JG |title=Obesity, fatty liver and liver cancer |journal=HBPD INT |volume=4 |issue=2 |pages=173-7 |year=2005 |pmid=15908310 |doi=}}</ref>. | Up to 10% of cirrhotic alcoholic FLD will develop [[hepatocellular carcinoma]]. Overall incidence of liver cancer in non-alcoholic FLD has not been assessed yet but the association is well established.<ref>{{cite journal |author=Qian Y, Fan JG |title=Obesity, fatty liver and liver cancer |journal=HBPD INT |volume=4 |issue=2 |pages=173-7 |year=2005 |pmid=15908310 |doi=}}</ref> | ||
A retrospective [[cohort study]] concluded that [[liver failure]] is the main cause of morbidity and mortality in NASH-associated cirrhosis. The prognosis is either similar or less severe than HCV-cirrhosis.<ref name="pmid12883486">{{cite journal |author=Hui JM, Kench JG, Chitturi S, ''et al'' |title=Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C |journal=Hepatology |volume=38 |issue=2 |pages=420–7 |year=2003 |pmid=12883486 |doi=10.1053/jhep.2003.50320}}</ref> | |||
* http://nafldscore.com/ | |||
==Prognosis== | |||
Prognosis can be determined by: | |||
* FIB-4 | |||
* Liver stiffness measurement | |||
** Vibration-controlled elastography (VCTE), Fibroscan | |||
** Magnetic resonance elastography (MRE) | |||
==References== | ==References== | ||
| Line 12: | Line 25: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Hepatology]] | |||
[[Category:Medical conditions related to obesity]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
Latest revision as of 04:00, 2 June 2023
|
Fatty Liver Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fatty liver natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Fatty liver natural history, complications and prognosis |
|
FDA on Fatty liver natural history, complications and prognosis |
|
CDC on Fatty liver natural history, complications and prognosis |
|
Fatty liver natural history, complications and prognosis in the news |
|
Blogs on Fatty liver natural history, complications and prognosis |
|
Risk calculators and risk factors for Fatty liver natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Natural History
Complications
Up to 10% of cirrhotic alcoholic FLD will develop hepatocellular carcinoma. Overall incidence of liver cancer in non-alcoholic FLD has not been assessed yet but the association is well established.[1]
A retrospective cohort study concluded that liver failure is the main cause of morbidity and mortality in NASH-associated cirrhosis. The prognosis is either similar or less severe than HCV-cirrhosis.[2]
Prognosis
Prognosis can be determined by:
- FIB-4
- Liver stiffness measurement
- Vibration-controlled elastography (VCTE), Fibroscan
- Magnetic resonance elastography (MRE)
References
- ↑ Qian Y, Fan JG (2005). "Obesity, fatty liver and liver cancer". HBPD INT. 4 (2): 173–7. PMID 15908310.
- ↑ Hui JM, Kench JG, Chitturi S; et al. (2003). "Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C". Hepatology. 38 (2): 420–7. doi:10.1053/jhep.2003.50320. PMID 12883486.